Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia

International Angiology

Volumn 29, Issue 6, 2010, Pages 514-524

  Avellone, G ^a   Di Garbo, V ^a   Guarnotta, V ^a   Scaglione, R ^a   Parrinello, G ^a   Purpura, L ^a   Torres, D ^a   Campisi, D ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Cholesterol; Ezetimibe; Hypercholesterolemia; LDL; Simvastatin

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C REACTIVE PROTEIN; CHOLESTEROL; EZETIMIBE; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; ARTERY INTIMA PROLIFERATION; ARTICLE; CHOLESTEROL BLOOD LEVEL; CREATINE KINASE BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MYOPATHY; PAIN; RHABDOMYOLYSIS; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ANALYSIS OF VARIANCE; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; AZETIDINES; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CAROTID ARTERY DISEASES; CHOLESTEROL; CHOLESTEROL, HDL; DRUG COMBINATIONS; FEMALE; FIBRINOGEN; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; INFLAMMATION MEDIATORS; ITALY; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PRIMARY PREVENTION; SECONDARY PREVENTION; SIMVASTATIN; TIME FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 79952305264     PISSN: 03929590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Brown MS, Goldstein JL. A receptor mediated pathway for cholesterol homeostasis. Science 1986;232:34-47. (Pubitemid 16037973)
2. Hobbs HH, Brown MS, Goldstein JL. Molecular genetics of the LDL receptor gene in Familial Hypercholesterolemia. Human Mutat 1992;1:445-6.
3. Avellone G, Di Garbo V, Abruzzese G, Campisi D, De Simone R et al. One-year atorvastatin treatment in hypercholesterolemic patients with or without carotid artery disease. Int Angiol 2006;25:26-34.
4. The Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease:The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
5. Rouleau J. Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen: results from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) trial. Am J Med 2005;12A:28-35.
6. Blazing MA, De Lemos JA, Dyke CK, Califf RM, Bilheimer D, Braunwald E. The A-to-Z Trial: Methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy. Am Heart J 2001;142:211-7.
7. Wilkinson B, Cockcroft JR. Cholesterol, endothelial function and cardiovascular disease. Curr Opin Lipidol 1998;9:237-42. (Pubitemid 28274354)
8. Rosenson RS, Tangney CC. Antiatherotrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998;279:1643-60.
9. Lacoste L, Lam JYT, Hung J, Letchacovski G, Solymoss CB, Waters D. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995;92:3172-7.
10. Di Garbo V, Cordova R, Avellone G. Increased in vivo thrombin generation and complement activation in patients witj type IIa hyperlipoproteinemia:effects of simvastatin treatment. Current Therapeutic Research 1997;58:706-23. (Pubitemid 27497619)
11. Rader DJ, Cohen J, Hobbs HH. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J Clin Invest 2003;111:1795-803. (Pubitemid 38057721)
12. Wiegman A, De Groot E, Hutten BA, Rodenburg J, Gort J, Bakker HD et al. Arterial intima-media thickness in children heterozygous for familial hypercholesterolaemia. Lancet 2004;363:369-70. (Pubitemid 38169546)
13. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJP, Stalenhoef AFH. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP): a prospective, randomized, double-blind trial. Lancet 2001;357:577-81. (Pubitemid 32179609)
14. Pedersen TR, Faergeman O, Holme I, Olsson AG, Tikkanen MJ. Effect of greater LDL-C reduction on prognosis: The Incremental Decrease in Endpoints through Aggressive Lipid Lowering (IDEAL) trial. Atherosclerosis 1994;144(Suppl 1):38.
15. Bellosta S, Bernini F, Ferri N, Quarato P, Canavesi M, Arnaboldi L. Direct vascular effects of HMG-CoA reductase inhibitors. Atherosclerosis 1998;137;S101-S109.
16. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB et al. National Heart, Lung, and Blood Institute; American College of Cardiology Foundation;American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39.
17. Garcia-Calvo M, Lisnock J, Bull HG, Hawes BE, Burnett DA, Braun MP et al. The target of ezetimibe is Niemann-Pick Cl-Like 1 (NPC1L1). Proc Natl Acad Sci USA 2005;102:8132-7.
18. Altmann SW, Davis HR Jr, Zhu LJ, Yao X, Hoos LM, Tetzloff G et al. Niemann-Pick Cl Like 1 protein is critical for intestinal cholesterol absorption. Science 2004;303:1201-4. (Pubitemid 38233587)
19. Davidson MH, McGarry T, Bettis R, Melani L, Lipka LJ, LeBeault AP et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002;40:2125-34. (Pubitemid 36005898)
20. Gagne C, Bays HE, Weiss SR, Mata P, Quinto K, Melino M et al. Ezetimibe Study Group. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002;90:1084-91. (Pubitemid 35339435)
21. Sager PT, Melani L, Lipka L, Strony J, Yang B, Suresh R et al. Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein. Am J Cardiol 2003;92:1414-8. (Pubitemid 37532562)
22. Melani L, Mills R, Hassman D, Lipetz R, Lipka L, LeBeault A et al. Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Eur Heart J 2003;24:717-28.
23. Familial hypercholesterolemia (FH): report of a WHO consultation. Geneva: World Health Organization; 1998.
24. Pignoli Pi, Tremoli E, Poli A, Oreste P, Paoletti R. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation 1986;74:1399-403.
25. Sudhop T, Lutjohann D, Kodal A, Igel M, Tribble DL, Shah S et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002;106:1943-8.
26. Farmer M. Ezetimibe in hypercholesterolaemia. Int J Clin Pract 2002;56:611-4.
27. Matsuo T, Iwade K, Hirata N, Yamashita M, Ikegami H, Tanaka N et al. Improvement of arterial stiffness by the antioxidant and anti-inflammatory effects of short-term statin therapy in patients with hypercholesterolemia. Heart Vessel 2005;20:8-12. (Pubitemid 40260300)
28. Shinohara K, Shoji T, Kimoto E, Yokoama H, Fujiwara S, Hatsuada S et al. Effect of atorvastatin on regional arterial stiffness in patients with type 2 diabetes mellitus. J Atheroscler Thromb 2005;12:205-10.
29. Corsini A, Pazzucconi F, Arnaboldi L, Pfister P, Fumagalli R, Paoletti R, Bernini F. Direct effects of statins on tha vascular wall. J Cardiovasc Pharmacol 1998;31:773-8.
30. Ichilara A, Hayashi M, Koura Y, Tada Y, Kaneshiro, Saruta T. Long-term effects of statins on arterial pressure and stiffness of hypertensive. J Hum Hypertens 2005;19:103-9. (Pubitemid 40220632)
31. Landmesser U, Bahlmann F, Mueller M, Spiekermann S, Kirchhoff N, Schulz S et al. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 2005;111:2356-63. (Pubitemid 40647072)
32. Bard JM, Dallongeville J, Hagen E, Pfister P, Ose L, Fruchart JC, Duriez P. Comparison of the effect of fluvastatin, on hydroxymethyl glutaryl coenzyme A reductase inhibitor, and cholestyramine, a bile acide sequestrant, on lipoprotein particles defined by apolipoprotein composition. Metabolism 1995;44:1447-54.
33. Seifert S, Kazatchkine MD. The complement system and atherosclerosis. Atherosclerosis 1988;73:91-104.
34. Strano A, Davi G, Novo S, Avellone G. Thrombophilic states and atherosclerosis. In: Crepaldi G, Fellin R, Olsson AG, Toffano G, eds. Arteriosclerosis Brain Disease. New York: Raven Press; 1983. p. 173-80.
35. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557-65. (Pubitemid 35315836)
36. Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relationship of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Am J Epidemiol 1996;144:537-47. (Pubitemid 26304398)
37. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352:1191-3.
38. Ridker PM. The time for cardiovascular inflammation reduction trials has arrived:how low to go for hs-CRP. Arterioscler Thromb Vasc Biol 2008;28:1222-4.
39. Cremonesi A, Castriota F, Manetti R, Balestra G, Liso A. Endovascular treatment of carotid atherosclerotic disease:early and late out come in a non-selected population. Ital Heart J 2000;1:801-9. (Pubitemid 32056947)
40. Wiegman A, De Groot E, Hutten BA, Rodenburg J, Gort J, Bakker HD et al. Arterial intima-media thickness in children hetreozygous for familial hypercholesterolaemia. Lancet 2004;363:369-70. (Pubitemid 38169546)
41. Chambless L, Heiss G, Folsom AR, Rosamond W, Szklo M, Sharrett AR et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: The Atherosclerosis Risk in Communities (ARIC) Study. Am J Epidemiol 1997;146:483-94. (Pubitemid 27391409)
42. Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima-media thickness. Circulation 2002;106:2055-60. (Pubitemid 35192810)
43. Kastelein JJP, van Leuven SI, Burgess L, Evans GW, Kuivenhoven JA, Barter PJ et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007;356:1620-30. (Pubitemid 46631671)
44. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF et al. Simvastatin with or without Ezetimibe in Familial Hypercholesterolemial. (ENHANCE TRIAL) N Engl J Med 2008;358:1431-43. (Pubitemid 351482735)
45. Fleg JL, Mete M,Howard BV, Umans JG, Roman MJ, Ratner RE et al. Effect of statins alone versus statin plus ezetimibe on carotid atherosclerosis in type 2 diabetes. The SANDS (Stop Atherosclerosis in Native Diabetics Study) Trial J Am Coll Cardiol 2008;52:2206-9.